CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
发明人:
IBÁÑEZ CABEZA, Borja,CLINTON, Enda Joseph,GARCÍA-RUIZ, Jose Manuel,AGÜERO RAMON-LLIN, Jaume,FERNÁNDEZ-JIMÉNEZ, Rodrigo,FUSTER CARULLA, Valentín,LARA-PEZZI, Enrique,BERNAL RODRÍQUEZ, Juan Antonio,GALÁN
申请号：
EPEP2018/052168
公开号：
WO2018/138360A1
申请日:
2018.01.29
申请国别(地区):
WO
年份:
2018
代理人:
摘要：
The present invention relates to the field of medicine and biotechnology. More specifically it relates to oxygen carrier compositions for the delivery of oxygen to tissues and organs (e.g., to the myocardium) under bloodless situations. It further relates to medical uses and methods of treatment comprising the administration thereof, for instance, as delivery vehicle for gene therapy purposes. In a particular embodiment, it relates to an oxygen carrier composition for use in a method for the in vivo diagnosis and/or treatment of a myocardial disease wherein said method comprises the following consecutive steps: i. temporary occluding a coronary artery, and optionally, temporary occluding a coronary vein ii. administering into the coronary artery downstream to the site of occlusion the oxygen carrier composition, wherein said oxygen carrier composition has been pre-oxygenated and iii. administering into the coronary artery downstream to the site of occlusion a diagnostic, prophylactic and/or therapeutic agent and the oxygen carrier composition wherein the oxygen carrier composition in ii) is substantially free of the diagnostic, prophylactic and/or therapeutic agent administered in iii) and wherein in step iii) the agent and the oxygen carrier composition are administered simultaneously.La présente invention concerne le domaine de la médecine et de la biotechnologie. Plus spécifiquement, linvention concerne des compositions support doxygène pour ladministration doxygène à des tissus et des organes (par exemple, au myocarde) dans des situations non sanglées. Linvention concerne en outre des utilisations médicales et des procédés de traitement comprenant ladministration de celles-ci, par exemple, en tant que véhicule dadministration à des fins de thérapie génique. Dans un mode de réalisation particulier, linvention concerne une composition support doxygène destinée à être utilisée dans un procédé de diagnostic et/ou de traitement in vivo dune maladie myocardique ledit
